drugset / Trial / NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Timeline
- Start
- 2023-01-02
- Primary completion
- 2028-02-28
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NELDALEUCEL | Cell therapy | 200 cells | — |
| Subject | NELDALEUCEL | Cell therapy | 400 cells | — |